Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 10/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800214 | 0.90 | FAAH (0.40) | CNR1CNR2FAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL5782662 | 0.89 | TACR1 (0.47) | CNR1CNR2CYP3A4FAAHRORC | |
| SCHEMBL5804489 | 0.89 | GRIN2B (0.47) | CNR1CNR2FAAH | |
| Selonabant SCHEMBL4075847 | 0.88 | CNR1 (0.49) | CNR1CNR2FAAH | |
| Selonabant SCHEMBL29482761 | 0.88 | CNR1 (0.49) | CNR1CNR2FAAH | |
| Selonabant SCHEMBL4075536 | 0.88 | CNR1 (0.49) | CNR1CNR2FAAH | |
| Selonabant SCHEMBL4075537 | 0.88 | CNR1 (0.49) | CNR1CNR2FAAH | |
| Selonabant SCHEMBL31259163 | 0.88 | CNR1 (0.49) | CNR1CNR2FAAH | |
| SCHEMBL4089353 | 0.88 | RORC (0.44) | CNR1CNR2FAAHRORCTACR1 | |
| SCHEMBL4084803 | 0.88 | TACR1 (0.45) | CNR1CNR2CYP3A4CYP3A5FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |